While the efficacy of EZH2 inhibitors in RMC is still unknown, several small‐scale studies have demonstrated a response with bortezomib or platinum‐based combination chemotherapies, such as MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin).6, 17, 18, 19 Bortezomib is a known anticancer medication that is currently used to treat multiple myeloma and mantle cell lymphoma and targets the ubiquitin‐proteasome pathway (UPP) by binding the catalytic site of the 26S proteasome. The gene discussed is EZH2; the disease is plasma cell myeloma.